Company Overview

To develop its leading drug candidate SCENESSE(afamelanotide 16mg)for the treatment of a range of severe skin disorders.

Directors and Management

Ms Brenda Mary Shanahan

Non-Executive Director 06/12/2007

Mrs Shanahan is a pioneer in the Australian finance community. The first female stockbroker, Mrs Shanahan has also spent more than two decades working and investing in medical R&D and commercialisation. She is currently a non-executive director of Phoslock Water Solutions Ltd. Mrs Shanahan is also a non-executive director of DMP Asset Management Ltd and SG Hiscock Ltd, a director of the Kimberly Foundation of Australia Ltd, and Chair of the Aikenhead Centre for Medical Discovery in Melbourne. Previously Mrs Shanahan was a member of the Australian Stock Exchange and an executive director of a stockbroking firm, a fund management company and an actuarial company. Until 2017, she was Chair of St Vincent's Medical Research Institute. Mrs Shanahan was formerly Chair of Challenger Listed Investments Ltd. Her experience across global markets and medical research provides value to the current Board and Group. She is Chair of the Audit and Risk Committee and member of the Nomination Committee

AO, Doctorate (Hons),BCom, FAICD, ASIA, Grad(Eco & Female

Mrs Susan (Sue) Smith

Non-Executive Director 23/09/2019

Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.

Female

Dr Philippe J Wolgen

Chief Executive Officer,Managing Director 01/12/2005

Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.

MBA, MD Male

Mr Willem A Blijdorp

Non-Executive Director,Non-Executive Chairman 21/01/2015

Mr Blijdorp is an internationally recongnised entrepreneur who has helped build the B&S Group, one of the largest global trading houses, in a period spanning three decades. Willem now serves on its Supervisory Board and is a majority shareholder, focussing on the Group's development and expansion strategy. Mr Blijdorp was recognised for his expertise in merger and acquisitions and commercial leadership as the Ernst & Young Entrepreneur of the Year in the Netherlands, and runner-up in its European Union awards. He is a Chair member of Remuneration and Nomination committee. He is also member of the Audit and Risk Committee.

HLFUKIoD Male

Dr Karen Agersborg

Non-Executive Director 29/01/2018

Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.

Doct(Oesteopathic Med),MAOA,FAACE,FACOI, Endocrinologist Female

Dr Jeffrey Rosenfeld

Non-Executive Director 26/11/2019

Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.

OBE,AC, Neurosurgeon Male

Top 20 Shareholders

Director Transactions